- Potential subjects must be newly diagnosed with advanced Melanoma and received no treatment for the advanced disease The subjects who received previous primary treatment and any additional treatment (which is given after the primary treatment) are permitted if it was completed at least 6 weeks prior to study entry and if the side effects of the treatment are resolved If subjects received any of the following primary treatment previously; they are not permitted to be enrolled in the study (anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2, or any other drug specifically targeting T-cell costimulation or checkpoint pathways such as anti-CD-137)